KinasePro

Kinase Chemistry – Just a year and a half behind the times.

XL-765

Posted by kinasepro on April 25, 2007

mTOR / Pi3k inhibitor IND application reported today. XL-147 is their other one, and three pi3k applications published last Thursday. WO/2007/044698, WO/2007/044729, WO/2007/044813

Till Nature disables hotlinking: here’s who’s got what from here.

Advertisements

2 Responses to “XL-765”

  1. newtothefield said

    It seems like Exelixis has been extremely successful in the last three years (13 INDs with oncology applications). Do you think they are being less-selective when it comes to IND selection than other groups?

  2. kinasepro said

    Thats a pretty deep question… I know they read the blog though, so how ’bout it Ex?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

 
%d bloggers like this: